Boothbay Fund Management’s Amicus Therapeutics FOLD Stock Holding History

Boothbay Fund Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$412K	Sell	28,472 -205,185	-88%	-$2.94M	0.01%	1447
2025 Q4	$3.33M	Buy	+233,657	New	+$2.3M	0.05%	426
2024 Q4	–	Sell	-24,857	Closed	-$265K	–	1639
2024 Q3	$265K	Buy	+24,857	New	+$271K	0.01%	1304
2022 Q4	–	Sell	-13,553	Closed	-$141K	–	2138
2022 Q3	$141K	Buy	+13,553	New	+$151K	﹤0.01%	1956
2022 Q1	–	Sell	-16,530	Closed	-$191K	–	2357
2021 Q4	$191K	Sell	16,530 -42,562	-72%	-$474K	﹤0.01%	1506
2021 Q3	$564K	Buy	59,092 +304	+0.5%	+$3.11K	0.02%	1029
2021 Q2	$567K	Buy	58,788 +14,767	+34%	+$144K	0.02%	943
2021 Q1	$435K	Buy	+44,021	New	+$681K	0.02%	1009

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Boothbay Fund Management's FOLD Position: Q1 2026 in Review

Boothbay Fund Management reduced its Amicus Therapeutics (FOLD) stake by 88% in Q1 2026, selling an estimated $2.94M and leaving 28,472 shares worth $412K. The position accounts for 0.01% of the portfolio, ranked #1447.

Boothbay Fund Management first reported a position in FOLD in Q1 2021 and has held it in 8 quarters since. The position peaked at $3.33M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Boothbay Fund Management held 28,472 shares of Amicus Therapeutics worth $412K as of Q1 2026.
Boothbay Fund Management sold 205,185 Amicus Therapeutics shares in Q1 2026, an estimated $2.94M.
Amicus Therapeutics made up 0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1447 holding.
Boothbay Fund Management first reported a position in Amicus Therapeutics in Q1 2021 and has held it in 8 quarters since.
Boothbay Fund Management's Amicus Therapeutics position peaked at $3.33M in Q4 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.